There are many reasons your immune system might react differently to vaccines.
Academic rigour, journalistic flair
Articles on COVID-19 vaccines
Displaying 321 - 340 of 576 articles
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
As Australian women over 50 prepare to have their COVID shot, they need to factor in timing of their mammogram. Here’s why.
Can companies legally require workers to get vaccinated? Employers have gotten so good at finding ways to get employees to comply with their policies that it may not matter.
It’s cheap and easy to store, but the Russian vaccine does not yet have approval in Europe.
There are two schools of thought.
Side effects generally indicate a natural immune response and will resolve in a few days.
Our best long-term strategy is to rely on the mRNA vaccines like Pfizer and Moderna.
COVID-19 has shown us that we are not “all in this together” despite what politicians may want us to think.
Due to early logistical planning, Rwanda had the capacity to store 5 million doses before the vaccines arrived.
New study looks at public attitudes to COVID-19 vaccine aid. The results are reassuring.
It’s normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won’t tell you which you are.
The amount of risk from overseas arrivals depends not just on Australia’s vaccination rates, but also on the particular circumstances of the country from which people are travelling.
As more people get vaccinated and different facets of society slowly reopen, challenges remain in the nation’s quest to get back to normal. Here are five articles that help illuminate the path.
Variants of the original SARS-CoV-2 are now in wide circulation. That means the third wave of COVID-19 has come with new questions about the variants, their effects and what might come next.
After a massive reduction in COVID case numbers and optimism about the vaccine rollout, India has seen a huge second wave of infections.
The fight for vaccine equity needs to stop looking to multilateral institutions for permission and instead focus on the policy tools that are already available to states.
If one adenoviral vaccine is linked with blood clots, it doesn’t mean all vaccines in this family will have that same effect. But it’s definitely worth health authorities assessing the data.
The one-dose vaccine developed by Johnson & Johnson is temporarily halted because of potentially serious blood clots seen in six women. An immunologist explains what this means for you.
A vaccine expert breaks down everything you need to know about the Novavax vaccine.
Top contributors
-
Associate professor, UNSW Sydney
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Assistant Professor of Political Science, Oklahoma State University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Chair in Epidemiology, Deakin University
